gms | German Medical Science

73. Jahrestagung der Deutschen Gesellschaft für Neurochirurgie (DGNC)
Joint Meeting mit der Griechischen Gesellschaft für Neurochirurgie

Deutsche Gesellschaft für Neurochirurgie (DGNC) e. V.

29.05. - 01.06.2022, Köln

Gross total resection as a significant factor in the treatment of infant Glioblastoma

Maximale Resektion als signifikanter Faktor in der Behandlung des Glioblastomes bei Kindern

Meeting Abstract

  • presenting/speaker Hanah Gull - Universitätsklinikum Essen, Klinik für Neurochirurgie und Wirbelsäulenchirurgie, Essen, Deutschland
  • Marvin Darkwah Oppong - Universitätsklinikum Essen, Klinik für Neurochirurgie und Wirbelsäulenchirurgie, Essen, Deutschland
  • Oliver Gembruch - Universitätsklinikum Essen, Klinik für Neurochirurgie und Wirbelsäulenchirurgie, Essen, Deutschland
  • Laurèl Rauschenbach - Universitätsklinikum Essen, Klinik für Neurochirurgie und Wirbelsäulenchirurgie, Essen, Deutschland
  • Alejandro Santos Saint Romain - Universitätsklinikum Essen, Klinik für Neurochirurgie und Wirbelsäulenchirurgie, Essen, Deutschland
  • Ramazan Jabbarli - Universitätsklinikum Essen, Klinik für Neurochirurgie und Wirbelsäulenchirurgie, Essen, Deutschland
  • Philipp Dammann - Universitätsklinikum Essen, Klinik für Neurochirurgie und Wirbelsäulenchirurgie, Essen, Deutschland
  • Neriman Oezkan - Universitätsklinikum Essen, Klinik für Neurochirurgie und Wirbelsäulenchirurgie, Essen, Deutschland
  • Karsten H. Wrede - Universitätsklinikum Essen, Klinik für Neurochirurgie und Wirbelsäulenchirurgie, Essen, Deutschland
  • Ulrich Sure - Universitätsklinikum Essen, Klinik für Neurochirurgie und Wirbelsäulenchirurgie, Essen, Deutschland
  • Yahya Ahmadipour - Universitätsklinikum Essen, Klinik für Neurochirurgie und Wirbelsäulenchirurgie, Essen, Deutschland

Deutsche Gesellschaft für Neurochirurgie. 73. Jahrestagung der Deutschen Gesellschaft für Neurochirurgie (DGNC), Joint Meeting mit der Griechischen Gesellschaft für Neurochirurgie. Köln, 29.05.-01.06.2022. Düsseldorf: German Medical Science GMS Publishing House; 2022. DocV058

doi: 10.3205/22dgnc064, urn:nbn:de:0183-22dgnc0646

Published: May 25, 2022

© 2022 Gull et al.
This is an Open Access article distributed under the terms of the Creative Commons Attribution 4.0 License. See license information at http://creativecommons.org/licenses/by/4.0/.


Outline

Text

Objective: Malignant gliomas are the most frequently fatal disease among children and adolescents. However, they are rare as they account for only 1% of all cancerous diseases in patients under 18 years. In Germany, glioblastoma (GBM) in this age group amounts to 60 cases per year. A standard radio- and chemotherapy, as well as surgical procedure, is not optimized so far. Surviving children show more therapy-associated side effects in the long run. This study aimed to investigate the course of glioblastoma in children.

Methods: Medical records of children (age < 15 years) with GBM treated in our institution between 2006 and 2018 were analyzed regarding demographic-, clinical-, molecular characteristics, and outcome. Univariate and multivariate analyses were performed to determine significant coherences (p-value ≤ 0,05 was considered statistically significant).

Results: Of 889 patients treated for GBM from 01/2006 to 12/2018, 20 were younger than 15 years old with a mean age of 8.65 (± 4.97 SD). The male to female ratio was 1.22: 1. Pregnancy and birth were passed uncomplicated in all cases. All patients who did not die in the early postoperative period (n= 16) underwent radiotherapy and chemotherapy after surgical treatment. The extent of tumor resection represented the most prominent prognostic factor for overall survival (OS) in univariate and Cox regression analyses (p < 0.001). Eight patients underwent a gross total resection (GTR), 7 underwent a subtotal resection, and 5 had a stereotactic biopsy (SB). After GTR and adjuvant radio- and chemotherapy, the mean OS was 54.50 months (± 71.21 SD). While the mean OS after subtotal resection (STR) was only 1.21 months (± 0.39 SD), the mean OS in the group achieving a SB amounted 5.6 months (± 4.34 SD). GTR was significantly correlated with a longer patients’ overall survival (Log Rank p < 0.001).

Conclusion: Despite the same histology, OS differs between children and adults with GBM. The findings of our database indicate that STR shows no advantage over SB for younger patients. Further investigations are urgently needed to establish standard management of glioblastoma in children.